Search

Addressing the bureaucracy challenge

EHA has recently brought key stakeholders around the table to discuss bureaucratic obstacles in clinical research.

Read more

SGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates among Older Patients with AML

Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.

Read more

Highlights of Past EHA (HOPE) MENA 2021

For the upcoming edition of the Highlights of Past EHA (HOPE) Middle East and North Africa (MENA), EHA will organize a truly regional meeting by collaborating simultaneously with our hematology partners from the region.

Read more

Policy on life events

EHA has a policy on life events and eligibility. If you're submitting a grant application and the policy applies to your circumstances, you can ask us to extend the period of eligibility.

Read more

Policy on life events

EHA has a policy on life events and eligibility. If you're submitting a grant application and the policy applies to your circumstances, you can ask us to extend the period of eligibility.

Read more

Policy on life events

EHA has a policy on life events and eligibility. If you're submitting a grant application and the policy applies to your circumstances, you can ask us to extend the period of eligibility.

Read more

Policy on life events

EHA has a policy on life events and eligibility. If you're submitting a grant application and the policy applies to your circumstances, you can ask us to extend the period of eligibility.

Read more